PMID- 35439094
OWN - NLM
STAT- MEDLINE
DCOM- 20230922
LR  - 20230922
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 36
IP  - 5
DP  - 2023 Oct
TI  - A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients.
PG  - 1134-1141
LID - 10.1177/08971900221088793 [doi]
AB  - Introduction: Over the last few years, targeted therapy has become the mainstay 
      maintenance treatment of patients with ovarian cancer including patients with 
      BRCA1/BRCA2 mutations. Poly ADP ribose polymerase inhibitors (PARPi) are 
      effective in the treatment of patients who are in complete or partial remission. 
      PARPi are known to cause hematological adverse events (AEs), but have not been 
      compared directly to each other. Objective: Primary objective was to compare the 
      incidence of hematological and non-hematological AEs associated with the use of 
      PARPi. Methods: This was a single institution, retrospective study evaluating 
      patients who were treated with PARPi for ovarian cancer from January 2017 to 
      October 2020. Patients were stratified according to which PARP inhibitor they 
      received. Results: Ninety-two patients were included in final analysis. 
      Thirty-one (33.7%) patients received niraparib and 61 (66.3%) patients received 
      olaparib. Median age of patients were 64.3 (range, 33.8 to 92.3) years, 66 
      (71.7%) were white, and 84 (91.3%) had an ECOG PS of 0/1. Patients in the 
      niraparib group experienced a higher rate of hematologic AEs, with 11 (35.5%), 20 
      (64.5%), and 18 (58.1%) experiencing neutropenia, anemia, and thrombocytopenia, 
      respectively. Eight (13.1%), 24 (39.3%), and 16 (26.2%) patients in the olaparib 
      group experienced neutropenia, anemia, and thrombocytopenia, respectively. 
      Conclusion: This single institution retrospective study outlines the 
      hematological toxicities observed between two PARPi. Our results suggested that 
      niraparib tended to be associated with a higher risk for hematologic toxicities 
      than olaparib. Anemia was the most common hematologic toxicity which was 
      consistent with what has been widely documented in the literature.
FAU - Lee, Chung-Shien
AU  - Lee CS
AUID- ORCID: 0000-0003-3505-6402
AD  - St. John's University, College of Pharmacy and Health Sciences, Department of 
      Clinical Health Professions, 8000 Utopia Parkway, St. Augustine Hall Room B48, 
      Queens, NY, USA.
AD  - Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, 
      Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, 
      NY, USA. RINGGOLD: 537773
FAU - Hernandez, Jennifer
AU  - Hernandez J
AD  - Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, 
      Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, 
      NY, USA. RINGGOLD: 537773
FAU - Liang, Connie
AU  - Liang C
AD  - St. John's University, College of Pharmacy and Health Sciences, Department of 
      Clinical Health Professions, 8000 Utopia Parkway, St. Augustine Hall Room B48, 
      Queens, NY, USA.
FAU - Leung, Ashley
AU  - Leung A
AD  - St. John's University, College of Pharmacy and Health Sciences, Department of 
      Clinical Health Professions, 8000 Utopia Parkway, St. Augustine Hall Room B48, 
      Queens, NY, USA.
FAU - Stefanov, Dimitre G
AU  - Stefanov DG
AD  - Biostatistics Unit, The Feinstein Institutes for Medical Research, Manhasset, NY, 
      USA. RINGGOLD: 88982
FAU - Cheng, Kit
AU  - Cheng K
AD  - Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, 
      Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, 
      NY, USA. RINGGOLD: 537773
FAU - John, Veena
AU  - John V
AD  - Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, 
      Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, 
      NY, USA. RINGGOLD: 537773
LA  - eng
PT  - Journal Article
DEP - 20220419
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Female
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - Poly(ADP-ribose) Polymerase Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - *Antineoplastic Agents/adverse effects
MH  - *Ovarian Neoplasms/drug therapy/genetics
MH  - *Anemia
MH  - *Neutropenia/chemically induced
MH  - *Thrombocytopenia/chemically induced
OTO - NOTNLM
OT  - niraparib
OT  - olaparib
OT  - ovarian cancer
OT  - poly (ADP-ribose) polymerase inhibitors
OT  - rucaparib
EDAT- 2022/04/20 06:00
MHDA- 2023/09/22 06:42
CRDT- 2022/04/19 17:11
PHST- 2023/09/22 06:42 [medline]
PHST- 2022/04/20 06:00 [pubmed]
PHST- 2022/04/19 17:11 [entrez]
AID - 10.1177/08971900221088793 [doi]
PST - ppublish
SO  - J Pharm Pract. 2023 Oct;36(5):1134-1141. doi: 10.1177/08971900221088793. Epub 
      2022 Apr 19.